Heng Mei

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 37

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Blood cancer journal

British journal of haematology

Cancer communications (London, England)

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Zhaozhao Chen, Yu Hu, Heng Mei
Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies. Cancer communications (London, England) 44 (3) (2024)
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies. Cancer communications (London, England) 44 (3) (2024)
Xiaojuan Peng, Xialin Zhang, Meiling Zhao, Doudou Chang, Lin-Hua Yang, Heng Mei, Ruijuan Zhang
Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: A review. British journal of haematology 205 (2) (2024)
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies. Cancer communications (London, England) 44 (3) (2024)
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies. Cancer communications (London, England) (2024)
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies. Cancer communications (London, England) 44 (3) (2024)
Zhaozhao Chen, Yu Hu, Heng Mei
Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Min Xu, Jiachen Liu, Linlin Huang, Jinhui Shu, Qiuzhe Wei, Han Yan, Heng Mei
A novel scoring model for predicting efficacy and guiding individualised treatment in immune thrombocytopaenia. British journal of haematology (2024)
Zhaozhao Chen, Yu Hu, Heng Mei
Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Xiaojuan Peng, Xialin Zhang, Meiling Zhao, Doudou Chang, Lin-Hua Yang, Heng Mei, Ruijuan Zhang
Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: A review. British journal of haematology (2024)
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Han Yan, Heng Mei
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 13 (1) (2023)
Jianghua Wu, Lu Tang, Mengyi Du, Chenggong Li, Haiming Kou, Huiwen Jiang, Wenjing Luo, Yinqiang Zhang, Zhongpei Huang, Danying Liao, Wei Xiong, Heng Mei, Yu Hu
Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy. Clinical and translational medicine 13 (3) (2023)
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Han Yan, Heng Mei
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 13 (1) (2023)
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Han Yan, Heng Mei
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 13 (1) (2023)
Jianghua Wu, Lu Tang, Mengyi Du, Chenggong Li, Haiming Kou, Huiwen Jiang, Wenjing Luo, Yinqiang Zhang, Zhongpei Huang, Danying Liao, Wei Xiong, Heng Mei, Yu Hu
Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy. Clinical and translational medicine 13 (3) (2023)
Liang Wang, Heng Mei
Chimeric antigen receptor T-cell therapy, where are we now and where are we heading for. European journal of haematology 112 (1) (2023)
Zhaozhao Chen, Yu Hu, Heng Mei
Advances in CAR-Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Han Yan, Heng Mei
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 13 (1) (2023)
Xindi Wang, Chenggong Li, Wenjing Luo, Yinqiang Zhang, Zhongpei Huang, Jia Xu, Heng Mei, Yu Hu
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy. Annals of hematology (2023)
Chenggong Li, Jia Xu, Wenjing Luo, Danying Liao, Wei Xie, Qiuzhe Wei, Yinqiang Zhang, Xindi Wang, Zhuolin Wu, Yun Kang, Jin'e Zheng, Wei Xiong, Jun Deng, Han Yan, Heng Mei
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia (2023)
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Han Yan, Heng Mei
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 13 (1) (2023)
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Han Yan, Heng Mei
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 13 (1) (2023)
Chenggong Li, Jiachen Liu, Jun Deng, Jia Xu, Yun Kang, Wenjing Luo, Lei Chen, Han Yan, Heng Mei
Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report. British journal of haematology (2022)
Wenjing Luo, Chenggong Li, Yinqiang Zhang, Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC cancer 22 (1) (2022)
Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao, Zhiping Huang, Dan Jin, Tao Guo, Haiming Kou, Lin Liu, Lu Tang, Ping Yin, Zhihui Wang, Lisha Ai, Sha Ke, Yimeng Xia, Jun Deng, Lei Chen, Li Cai, Chunyan Sun, Linghui Xia, Gaoquan Hua, Yu Hu
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Journal of hematology & oncology 14 (1) (2021)
Heng Mei, Min Xu, Guolin Yuan, Feiyue Zhu, Jingming Guo, Ruibin Huang, Jun Qin, Tingting Lv, Fangmei Qin, Huili Cai, Ping Yin, Tingting Qin, Han Yan
A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. British journal of haematology 195 (5) (2021)
Lu Tang, Yinqiang Zhang, Han Yan, Heng Mei
T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies. BioMed research international 2021 (2021)
Weiqi Yao, Hongyun Gong, Heng Mei, Lei Shi, Jin-Ming Yu, Han Yan
Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme. Journal of oncology 2021 (2021)
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Andreas Stadlbauer, Chunyan Sun, Heng Mei, Martin Pecherstorfer, Latifa Bakiri, Erwin F Wagner, Giovanni Tonon, Martin Sattler, Han Yan, Pierfrancesco Tassone, Dirk Jaeger, Klaus Podar
JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia 35 (12) (2021)
Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang, Changcheng Zheng, Xuliang Shen, Qi Hu, Jing Liu, Jie Jin, Jianmin Luo, Yun Zeng, Sujun Gao, Xiao-Hui Zhang, Xin Zhou, Qingzhi Shi, Ruixiang Xia, Xiaobao Xie, Zhongxing Jiang, Li Gao, Yuansong Bai, Yan Li, Junye Xiong, Runzi Li, Jianjun Zou, Ting Niu, Renchi Yang, Han Yan
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study. Journal of thrombosis and haemostasis : JTH (2021)
Huiwen Jiang, Yu Hu, Heng Mei
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why? Biomarker research 8 (1) (2020)
Lu Tang, Jianghua Wu, Cheng-Gong Li, Hui-Wen Jiang, Min Xu, Mengyi Du, Zhinan Yin, Heng Mei, Yu Hu
Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (7) (2020)
Fan Zhou, Fen Zhou, Mengyi Du, Lin Liu, Tao Guo, Linghui Xia, Runming Jin, Yu Hu, Heng Mei
Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients. International journal of hematology 110 (5) (2019)
Lu Tang, Huan Zhang, Yi-Zhong Peng, Cheng-Gong Li, Hui-Wen Jiang, Min Xu, Heng Mei, Yu Hu
Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. BMC cancer 19 (1) (2019)
Huiwen Jiang, Chenggong Li, Ping Yin, Tao Guo, Lin Liu, Linghui Xia, Yaohui Wu, Fen Zhou, Lisha Ai, Wei Shi, Xuan Lu, Huafang Wang, Lu Tang, Qiuzhe Wei, Jun Deng, Runming Jin, Wei Xiong, Jian Dong, Heng Mei, Han Yan
Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. American journal of hematology 94 (10) (2019)
Heng Mei, Huiwen Jiang, Yaohui Wu, Tao Guo, Linghui Xia, Runming Jin, Yu Hu
Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. British journal of haematology 181 (5) (2017)